SHPMY Shanghai Pharmaceuticals Holdings Co., Ltd. Forecast, Technical & Fundamental Analysis

SHPMY in upward trend: 10-day moving average moved above 50-day moving average on June 24, 2025

The 10-day moving average for SHPMY crossed bullishly above the 50-day moving average on June 24, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

SHPMY moved above its 50-day moving average on June 24, 2025 date and that indicates a change from a downward trend to an upward trend.

Bearish Trend Analysis

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.716) is normal, around the industry mean (7.892). P/E Ratio (8.389) is within average values for comparable stocks, (29.460). Projected Growth (PEG Ratio) (2.467) is also within normal values, averaging (4.521). Dividend Yield (0.045) settles around the average of (0.032) among similar stocks. P/S Ratio (0.204) is also within normal values, averaging (35.215).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SHPMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SHPMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock worse than average.